Table 3. Logistic regression analyses for predictive pCR.
Univariate | Multivariate | |||
OR (95% CI) | P | OR (95% CI) | P | |
Age (year) | ||||
≥50 versus <50 | 2.13 (0.61–7.41) | 0.237 | ||
Tumor size (mm) | ||||
≥30 versus <30 | 0.76 (0.22–2.59) | 0.664 | ||
Nodal status | ||||
positive versus negative | 1.31 (0.39–4.47) | 0.664 | ||
ER status | ||||
positive versus negative | 0.19 (0.05–0.70) | 0.013 | 0.14 (0.02–0.78) | 0.025 |
PR status | ||||
positive versus negative | 0.09 (0.02–0.53) | 0.007 | ||
Ki67 labeling index (%) | ||||
≥30 versus <30 | 1.75 (0.42–7.30) | 0.442 | ||
Nuclear grade | ||||
3 versus 1, 2 | 1.12 (0.32–3.91) | 0.856 | ||
Tumor subtype | ||||
luminal/HER2 versus HER2 | 0.39 (0.20–0.77) | 0.007 | ||
PIK3CA mutational status | ||||
mutation versus wild type | 0.20 (0.03–1.19) | 0.076 | ||
PTEN expression | ||||
high versus low | 5.25 (1.23–22.4) | 0.025 | 0.62 (0.04–9.94) | 0.734 |
INPP4B | ||||
high versus low | 2.55 (0.48–13.5) | 0.271 | ||
pAkt expression | ||||
high versus low | 0.56 (0.12–2.60) | 0.459 | ||
PIK3CA copy number status | ||||
gain versus normal/loss | 1.36 (0.22–8.41) | 0.738 | ||
PI3K pathway activation | ||||
ahigh versus normal | 0.11 (0.03–0.48) | 0.003 | 0.05 (0.003–0.89) | 0.041d |
bhigh versus normal | 0.32 (0.07–1.41) | 0.134 | ||
chigh versus normal | 0.15 (0.04–0.63) | 0.01 | 0.14 (0.02–1.12) | 0.064e |
OR; odds ratio, CI; confidence interval, ER; estrogen receptor, PR; progesteron receptor, HER2; human epidermal growth factor 2, PTEN; phosphatase and tensin homolog, INPP4B; inositol polyphosphate 4-phosphatase-II.
high defined as PIK3CA mutation and/or PTEN low.
high defined as PTEN low and/or INPP4B low.
high defined as PIK3CA mutation and/or PTEN low and/or INPP4B low.
The value was indicated when each variable was included in the model, together with ER status and PTEN expression.